Article Text

Download PDFPDF

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
  1. Jieqing Chen1,2,
  2. Caitlin Creasy1,
  3. Carlos Antonio Torres-Cabala1,
  4. Suhendan Ekmekcioglu1,
  5. Sourindra N Maiti1,
  6. Charuta Kale1,
  7. Cara Haymaker1,
  8. Jason Roszik1,
  9. Roland L Bassett Jr1,
  10. Jianhua Hu1,
  11. Zhiqiang Wang1,
  12. Wencai Ma1,
  13. R Eric Davis1,
  14. Chantale Bernatchez1,
  15. Patrick Hwu1 and
  16. Laszlo Radvanyi2,3
  1. Aff1 grid.267308.80000000092062401M.D. Anderson Cancer Centre (MDACC)University of Texas Houston TX USA
  2. Aff2 Lion Biotechnologies Woodland Hills CA USA
  3. Aff3 grid.170693.a000000012353285XMoffitt Cancer Center Tampa FL USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Adoptive cell therapy using autologous TIL is a promising immunotherapy for metastatic melanoma. This study was aimed at finding predictive biomarkers in TIL patients, using IHC and gene expression analysis on original tumors used to expand TIL. The purpose was to find factors associated with optimal TIL outgrowth from melanoma tumors and ultimately clinical response to therapy. We found a significant differences in CD8, CD4 and CD3 staining in the tumors between good TIL growers and poor growers by IHC (p < 0.0001, respectively). Interestingly, the CD8 expression in the original tumors also correlated with the percentage of CD8+ T cells in the final TIL product after expansion. Using a new droplet digital PCR assay using TCR Vβ-specific primers called QuanTILfy™, we also found that good TIL growers had a higher TCR Vβ gene signal than samples from poor growers (p = 0.008 Mann-Whitney test) suggesting that this genetic test may be useful in selecting patients for TIL therapy. Gene expression profiling of 595 immunologically-relevant genes found differences in a number of genes in tumors of patients having good TIL growth versus poor TIL growth, such as CD8β and CD3δ, CD45RA, ICOS, PD-1, STAT4. Interestingly, CD8 gene expression was significantly correlated with immunosuppression pathway genes, such as PD-L1, PD-1, FoxP3, and IDO that was confirmed by IHC analysis. Strikingly, IHC analysis of these markers in original tumors, together with CD8, were also found to be predictive of overall survival (OS) after TIL infusion. There were also differences in key genes in tumors of clinical responders and non-responders to TIL treatment. One gene, IRAK1, was particularly interesting as it regulates NFkB signaling and pro-inflammatory cytokine production associated with decreased anti-tumor adaptive immunity. Both gene expression and IHC analysis found an association between higher IRAK1 and decreased OS and relapse-free survival after TIL infusion. In conclusion, our IHC and gene profiling assays on archived tumor samples have uncovered predictive biomarker signatures identifying patients eligible for TIL therapy and who will most likely benefit from TIL therapy, as well as possible new tumor resistance pathways to immunotherapy for melanoma that can be targets of novel combination therapies to enhance TIL therapy.